Advertisement

Topics

Latest "Daiichi Pharmaceutical" News Stories - Page: 4

01:59 EST 17th November 2018 | BioPortfolio

Here are the most relevant search results for "Daiichi Pharmaceutical" found in our extensive news archives from over 250 global news sources.

More Information about Daiichi Pharmaceutical on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Daiichi Pharmaceutical for you to read. Along with our medical data and news we also list Daiichi Pharmaceutical Clinical Trials, which are updated daily. BioPortfolio also has a large database of Daiichi Pharmaceutical Companies for you to search.

Showing "Daiichi Pharmaceutical" News Articles 76–100 of 8,800+

Probably Relevant

Fukushima Radiation Concentrated in Particles, Hot Spots

NewsA new report on Fukushima Daiichi’s radioactive contamination indicates that the estimates of how much radioactivity was released remain accurate, but where it is located and concentrated are a continual source of discovery.


M&As this week: JW Pharmaceutical, Lonza, Karo Intressenter

JW Pharmaceutical has acquired a 25% stake in Argonaut Therapeutics through a $2.6m investment. This move makes JW Pharmaceutical the second...Read More... The post M&As this week: JW Pharmaceutical, Lonza, Karo Intressenter appeared first on Pharmaceutical Technology.

Vernalis Research, a Ligand Company, Achieves Success Milestones in Collaboration with Daiichi Sankyo

Vernalis Research, a Ligand Company, announced today that it has earned multiple success milestones under its drug discovery collaboration with Daiichi Sankyo Company, Limited (Daiichi Sankyo) that began in December of 2017. The research utilizes Vernalis' fragment and structure-based drug discovery platform for two undisclosed oncology targets. A...


Phase 3 QuANTUM-R Study Demonstrates Daiichi Sankyo's Quizartinib Significantly Prolongs ...

QuANTUM-R study results showed that patients with relapsed/refractory acute myeloid leukemia (AML) with FLT3-ITD mutations who received single agent quizartinib had a 24 percent Read more...

Fukushima Radioactive Particle Release Was Significant Says New Research

NewsScientists say there was a significant release of radioactive particles during the Fukushima-Daiichi nuclear accident.Contributed Author

PTV News: Feb 1st, 2010

Top stories on February 1st, 2010: Targeting jobs: GSK’s plans to slash workforce Floating: Ironwood hopes to raise a quarter billion Flexion flexes muscles with four big pharmas Daiichi seeks Japanese approval for Laninamivir The ins and outs of tax-breaks for R&D Man boob bonanza: The surge in male breast reductions

AbbVie Soothes Safety Fears With More Upadacitinib RA Data

Following the fifth positive pivotal trial for AbbVie's JAK1 inhibitor in rheumatoid arthritis, it is looking increasingly likely that upadacitinib...   

Daiichi Sankyo Co Ltd 4568 Medical Equipment Deals and Alliances Profile [Report Updated: 24042018] Prices from USD $250

SummaryDaiichi Sankyo Company Ltd Daiichi Sankyo is a holding company that carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, overthecounter OTC drugs, and quasidrugs. The company classified its business operations into two segments, namely, Daiichi Sankyo Group segment and Ranbaxy Group segment. The ...

Daiichi Sankyo Co Ltd 4568 Medical Equipment Deals and Alliances Profile [Report Updated: 21092018] Prices from USD $250

SummaryDaiichi Sankyo Company Ltd Daiichi Sankyo is a holding company that carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, overthecounter OTC drugs, and quasidrugs. The company classified its business operations into two segments, namely, Daiichi Sankyo Group segment and Ranbaxy Group segment. The ...

Daiichi Sankyo Co Ltd 4568 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 16042018] Prices from USD $250

SummaryDaiichi Sankyo Company Ltd Daiichi Sankyo is a holding company that carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, overthecounter OTC drugs, and quasidrugs. The company classified its business operations into two segments, namely, Daiichi Sankyo Group segment and Ranbaxy Group segment. The ...

Daiichi Sankyo Co Ltd 4568 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 24092018] Prices from USD $250

SummaryDaiichi Sankyo Company Ltd Daiichi Sankyo is a holding company that carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, overthecounter OTC drugs, and quasidrugs. The company classified its business operations into two segments, namely, Daiichi Sankyo Group segment and Ranbaxy Group segment. The ...

First Filing From Bluebird And Daiichi Keeping Mum: A Status Report On Accelerated Assessment In The EU

As the European Medicines Agency gets on with its fast-track review of bluebird bio's LentiGlobin gene therapy, the Pink ...

Tazemetostat Setbacks Hit Epizyme

As drug fails in DLBCL, firm focuses on lifting partial clinical hold on other trials. A first filing in a...    

Genentech Mines The Microbiome Again With IBD Deal

Genentech is to work with microbiome therapeutics company Microbiotica in a collaboration to discover, develop and commercialise treatments for inflammatory...   

World Regulators Wrestle With Advanced Therapies

The development of advanced therapy medicinal products is dogged by a lack of regulation and guidance and differences in what...   

Daiichi Sankyo Seals Speedier Europe Review For Quizartinib

The acute myeloid leukemia drug is the lead candidate in the strong oncology pipeline the Japan-headquartered company has assembled over...   

AZ Clears Out Three Respiratory Drugs With Sale To Covis

The drug giant's strategy of divesting old assets continues apace with the $350m sale of the ciclesonide-based drugs Alvesco, Omnaris and...   

Pharmaceutical Portfolio Management Reading List

Portfolio, Program, and Project Management in the Pharmaceutical and Biotechnology Industries This book describes the way that pharmaceutical projects and programs are currently managed, and offers views from many highly… The post Pharmaceutical Portfo... The post Pharmaceutical Portfolio Management Reading List appeared first on Biotechblog.

FDA grants leukaemia drug ‘breakthrough’ status

A leukaemia drug has been granted ‘breakthrough therapy’ status by the US drug regulator. Daiichi Sankyo announced that it had been awarded the designation by the US Food and Drug Administration (FDA) for quizartinib, which is used to treat acute ...

Menopausal Symptoms Cooled By KaNDy's Dual Neurokinin Antagonist

Faster relief of debilitating menopausal symptoms in early-stage clinical trial results suggest a potential new class of products being evaluated...   

Daiichi's Phase III Quizartinib Data Pave Way In Niche AML Market

Showing an overall survival improvement in the especially hard to treat FLT3-ITD mutated patients is a significant achievement in AML...    

Pharmaceutical glass packaging market to grow at 6% CAGR

North America dominates the global market for pharmaceutical glass packaging, due to the region’s technical innovation and strong demand for pharmaceutical products... The post Pharmaceutical glass packaging market to grow at 6% CAGR appeared first on European Pharmaceutical Review.

Immunic AG: Immunic schließt globalen Options- und Lizenzvertrag mit Daiichi Sankyo ab

Dow Jones hat von EQS/DGAP eine Zahlung für die Verbreitung dieser Pressemitteilung über sein Netzwerk erhalten. DGAP-Media / 2018-11-05 / 09:00 *Immunic schließt globalen Options- und Lizenzvertr...

Teva Braces For A Bigger Hit As Price Competition Intensifies For Copaxone

Teva has been able to hold onto a roughly 85% share of the Copaxone 40 mg market, but expects pressure...   

How safe is your process? The usual causes of pharmaceutical contamination

Large-scale plant shutdowns are somewhat rare in the pharmaceutical industry, given the high level of care that manufacturers must take...Read More... The post How safe is your process? The usual causes of pharmaceutical contamination appeared first on Pharmaceutical Technology.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks